Electromechanical Mapping to Evaluate Heart Muscle

NCT00001895 | Completed Phase 3

• 2 other identifiers: 99015399-H-0153
• Study Type: interventional
• Target: 71
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with narrowed heart arteries who undergo coronary angiography (imaging of the heart's blood vessels) may participate in this "heart mapping" study designed to gain information about the condition of different areas of the heart muscle. In coronary angiography, a thin tube called a catheter is inserted through a small incision in the groin and pushed up to the heart. There, a contrast dye is injected, revealing areas of blockage in the coronary arteries-the vessels that supply blood to the heart muscle. As soon as the angiography is completed, patients in this study will undergo another procedure called "Biosense mapping." For this procedure, a special catheter with a tiny sensor at the tip will be inserted into the sheath that was used for the angiography and advanced to the heart's main pumping chamber-the left ventricle. The sensor detects the pattern of an electromagnetic field generated from a pad under the patient, and an image of the precise location of the catheter in 3-dimensional space can be seen on a computer screen. The catheter is then navigated to various precise locations in the ventricle, producing an electromechanical map that distinguishes scarred muscle tissue from healthy tissue-information that can be important in guiding treatment. When this mapping is completed, the patient will be given a drug called dobutamine to increase the heartbeat, and the mapping will be repeated. The heart may also be mapped while the heart rate is increased with a pacing catheter to simulate exercise. The test will be stopped if adverse side effects develop. Patients in the study will also have magnetic resonance imaging (MRI) and PET (positron emission tomography) scans to get additional information about the heart muscle, such as blood flow and metabolism rate.

Conditions

Myocardial Ischemia

Keywords

Electromechanical Mapping; Myocardial Viability; Myocardial Ischemia; Positron Emission Tomography; Magnetic Resonance Imaging

Interventions

FDG DRUG

NH(3) DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Male or female patients greater than or equal to 21 years undergoing diagnostic cardiac catheterization. Must not have unstable angina. No significant unprotected left main disease (greater than 50% stenosis). No recent myocardial infarction (less than 4 weeks). Females must not be pregnant or lactating. No chronic atrial fibrillation. No prosthetic heart valves. No significant aortic valve pathology (sclerosis or stenosis) which might prevent retrograde crossing of catheter across the aortic valve. No left ventricular thrombus seen on echo. No severe heart failure (NYHA Class 4). No severe ectopy (greater than 1 every 10 beats) or ventricular tachycardia. No active infections (fever and elevated white cell count). Patients will not be considered for this protocol because of contraindications to MRI scan, as stated below: Pacemaker Implanted defibrillator Cerebral aneurysm clips Swan Ganz catheter with electrodes for a thermistor Cochlear implants Insulin pumps Neural stimulator

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI): lead

Study Sites (1)

National Heart, Lung and Blood Institute (NHLBI)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Heyndrickx GR, Baig H, Nellens P, Leusen I, Fishbein MC, Vatner SF. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol. 1978 Jun;234(6):H653-9. doi: 10.1152/ajpheart.1978.234.6.H653.

  PMID: 665778 BACKGROUND

• Perrone-Filardi P, Bacharach SL, Dilsizian V, Maurea S, Marin-Neto JA, Arrighi JA, Frank JA, Bonow RO. Metabolic evidence of viable myocardium in regions with reduced wall thickness and absent wall thickening in patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol. 1992 Jul;20(1):161-8. doi: 10.1016/0735-1097(92)90153-e.

  PMID: 1607518 BACKGROUND

• Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med. 1990 Jul 19;323(3):141-6. doi: 10.1056/NEJM199007193230301.

  PMID: 2362606 BACKGROUND

MeSH Terms

Conditions

Myocardial Ischemia

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: November 4, 1999
• Study Start: August 1, 1999
• Study Completion: December 1, 2001
• Last Updated: March 4, 2008

Record last verified: 2001-12

Locations

US (1)